Submit an abstract for the ASH® Meeting on Lymphoma Biology. The deadline to submit is April 29, 2014, at 11:59 p.m. PDT.
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research
ASH is committed to helping practicing hematologists provide quality care to patients, continue their professional development, and enhance their knowledge and expertise.
Resources to help practitioners improve the quality of hematologic care provided to patients
Resources to support hematologists with both continuing medical education and maintaining board certification
Newly approved therapies and updates on shortages of hematologic drugs
Service that provides advice on clinical questions in one to two days
Information on federal programs and policies affecting clinical practice
Dr. Adam Cuker discusses the
use of platelet aggregation studies
in the evaluation of patients with a
suspected bleeding disorder.
Dr. Karen Quillen reviews her approach to the diagnosis and management of platelet alloimmunization.
Dr. Charles Quinn provides a detailed approach to selecting patients with sickle cell anemia for allogenic hematopoietic stem cell transplantation.
Dr. Huy P. Pham and Dr. Steven L. Spitalnik discuss their approach to the diagnosis their approach to the diagnosis and management of transfusion-related acute lung injury.
On April 17, 2014, the U. S. Food and Drug Administration approved ofatumumab (Arzerra Injection, for intravenous infusion; GlaxoSmithKline) in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.
FDA Approves Ibrutinib to Treat Chronic Lymphocytic Leukemia
In collaboration with the Food and Drug Administration (FDA), and as a service to our members, ASH provides information about newly approved therapies and other important FDA actions (e.g., updated safety information, ne
On November 13, 2013, the U. S. Food and Drug Administration granted accelerated approval to Ibrutinib (IMBRUVICA, Pharmacyclics, Inc.) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
On November 1, 2013, the U.S. Food and Drug Administration approved obinutuzumab (GAZYVA™ injection, for intravenous use, Genentech, Inc.; previously known as GA101) for use in combination with chlorambucil for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).
Earlier today, the U.S. House of Representatives passed a bill that would avert the more than 20% cut to Medicare physician payment mandated by the Sustainable Growth Rate (SGR) formula on April 1, 2014.
On February 6, 2014 the leadership of the House Ways and Means and Energy and Commerce Committees and the Senate Finance Committee released a bi-partisan and bicameral bill to repeal the Sustainable Growth Rate (SGR) formula that has driven annual reductions in Medicare payment for physician services.
Over the past two years, shortages of drugs and biologics used to treat patients with hematologic diseases, including leukemia and lymphoma, became critical and life-threatening.
Over the past year, ASH has been very active on physician payment issues.
Explore the ASH Academy, the eLearning platform for hematologists.
Submit quality measure data to the Centers for Medicare & Medicaid Services Physician Quality Reporting System (PQRS).
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology